Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection, a recombinant anti-IGF-1R antibody), Limertinib (EGFR TKI), Dupert® (fulzerasib, KRAS G12C inhibitor), DOVBLERON® (taletrectinib, ROS1 inhibitor), Retsevmo® (selpercatinib, RET inhibitor), and Jaypirca® (pirtobrutinib, BTK inhibitor).

PRNewsWire • Dec 7, 2025

Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology. “Until.

Business Wire • Dec 3, 2025

Nuvation Bio: A Strong Company Now Fairly Priced

Nuvation Bio (NUVB) is downgraded from Buy to Hold as its stock price now reflects improved Ibtrozi rollout visibility and strong fundamentals. Ibtrozi's commercial launch is robust, with early patient uptake and revenue run-rate supporting a $300–$600 million forward revenue estimate for NUVB. Despite a solid balance sheet and pipeline potential, NUVB's current valuation no longer offers the deep discount that justified aggressive buying at lower prices.

Seeking Alpha • Nov 29, 2025

Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL.

Business Wire • Nov 26, 2025

Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nuvation Bio Inc. ( NUVB ) Jefferies London Healthcare Conference 2025 November 19, 2025 10:00 AM EST Company Participants David Hung - Founder, President, CEO & Chairman Philippe Sauvage - CFO & Principal Financial Officer Conference Call Participants Farzin Haque - Jefferies LLC, Research Division Presentation Farzin Haque Jefferies LLC, Research Division Hi, everyone. My name is Farzin Haque.

Seeking Alpha • Nov 22, 2025

Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case

Nuvation Bio is demonstrating strong early commercial success with Ibtrozi, its newly FDA-approved therapy for ROS1-positive non-small cell lung cancer. NUVB reported 204 new patients for Ibtrozi in the latest quarter, supporting a robust revenue trajectory and validating the product's market potential. A conservative revenue projection supports NUVB's current market cap. The value of ex-US market rights of Ibtrozi, together with the rest of its product pipelines, provides further hedges.

Seeking Alpha • Nov 7, 2025

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Gary Hattersley, chief scientific officer at Nuvation Bio (NUVB +1.36%), exercised and immediately sold 100,000 shares of Class A common stock in an open-market derivative transaction on October 27, according to an SEC Form 4 filing.

The Motley Fool • Nov 3, 2025

Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript

Nuvation Bio Inc. ( NUVB ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Robert DeVita David Hung - Founder, President, CEO & Chairman Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - CFO & Principal Financial Officer Conference Call Participants Kaveri Pohlman - Clear Street LLC Farzin Haque - Jefferies LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Yaron Werber - TD Cowen, Research Division David Nierengarten - Wedbush Securities Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Presentation Operator Hello, and welcome to Nuvation Bio's Third Quarter 2025 Financial Results and Corporate Update Call. Today's call is being recorded, and a replay will be available.

Seeking Alpha • Nov 4, 2025

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We are thrilled that 204 new patients have received IBTROZI during our first full quarter as a commercial-stage company,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “Our early launch.

Business Wire • Nov 3, 2025